Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIG-HD: Intracerebral Grafting in Huntington's Disease
NCT00190450Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2002
- Primary completion
- Dec 2013
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of human fetal striatal cells in Huntington's disease (HD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Unified Huntington's Disease Rating Scale Total Motor Score. Started Jan 2002; status: completed.
02
Drugs
human fetal striatal cells
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT00190450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00190450.